If management is aware that the approval may face further delays, they should push to negotiate with their BP for an upfront investment—say, $25 million—with terms that can be adjusted later based on MHRA’s decision. This would help ease investor concerns and give the company the resources to move forward with other initiatives like DCVax-Direct trials, the Advent merger, and more. I strongly believe such a move would improve the share value and finally bring broader recognition from the biotech community.
And let’s be honest—if the BP is truly interested and believes MHRA approval is likely in the near future, a $25 million investment shouldn’t be a big deal for them. But again, we really don’t know—at this point, it’s hard to tell what’s real and what’s just rumor without any real substance.
Market Data 
Markets 
